Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

[1]  F. Boccardo,et al.  Management of young women with early breast cancer , 2018, ESMO Open.

[2]  Xiaohua Zeng,et al.  Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials , 2018, World Journal of Surgical Oncology.

[3]  O. Pagani,et al.  Should age impact breast cancer management in young women? Fine tuning of treatment guidelines , 2018, Therapeutic advances in medical oncology.

[4]  M. Thill,et al.  [The 20-year results of 5‑year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. , 2018, Der Internist.

[5]  M. Somerfield,et al.  Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Bruzzi,et al.  Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial , 2016, Supportive Care in Cancer.

[7]  Alberto Revelli,et al.  Cancer and fertility preservation: international recommendations from an expert meeting , 2016, BMC Medicine.

[8]  L. Boni,et al.  Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. , 2015, JAMA.

[9]  L. Newman,et al.  Breast Cancer in Young Women: Rare Disease or Public Health Problem? , 2015, JAMA oncology.

[10]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[11]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Barni,et al.  Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials , 2015, Breast Cancer Research and Treatment.

[13]  A. Partridge,et al.  Biology of breast cancer in young women , 2014, Breast Cancer Research.

[14]  E. Bar-Meir,et al.  Second international consensus guidelines for breast cancer in young women (BCY2). , 2014, Breast.

[15]  R. Tamimi,et al.  Prospective study of fertility concerns and preservation strategies in young women with breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Abbate,et al.  Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. , 2013, The American journal of cardiology.

[17]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[18]  Pietro Panizza,et al.  The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. , 2012, European journal of cancer.

[19]  K. Nordin,et al.  Change in working time in a population-based cohort of patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Ganz,et al.  Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[21]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[22]  L. Leibovici,et al.  Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2010, Journal of the National Cancer Institute.

[23]  C. Denkert,et al.  Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.

[24]  S. Missmer,et al.  The effects of paclitaxel, dose density, and trastuzumab on treatment‐related amenorrhea in premenopausal women with breast cancer , 2010, Cancer.

[25]  P. Bruzzi,et al.  Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. , 2005, Journal of the National Cancer Institute.

[26]  C. Hudis,et al.  Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane , 2005, Cancer.

[27]  Guido Knapp,et al.  Improved tests for a random effects meta‐regression with a single covariate , 2003, Statistics in medicine.

[28]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[29]  S. De Placido,et al.  Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. , 1991, British Journal of Cancer.

[30]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.